Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBG and Attention
NCT06115603Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Dec 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabigerol in attention deficit hyperactivity disorder (ADHD), sponsored by University of Arkansas. Started Dec 2024; status: completed.
02
Drugs
cannabigerol
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06115603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06115603.